Viking Therapeutics's Options: A Look at What the Big Money is Thinking
Portfolio Pulse from Benzinga Insights
Deep-pocketed investors have shown a bearish sentiment towards Viking Therapeutics (NASDAQ:VKTX), as revealed by Benzinga's tracking of public options records. The analysis of 13 extraordinary options activities indicates a divided mood among investors, with a significant lean towards bearishness. The options trading suggests a target price range of $55.0 to $90.0 for VKTX over the next three months. Despite this, professional analysts have set an average price target of $105.6, with varying ratings from Buy to Outperform. VKTX's current stock price is $75.22, with an RSI indicating a potential overbought situation. The company specializes in biopharmaceutical development for metabolic and endocrine disorders.
April 09, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viking Therapeutics shows a bearish sentiment among big investors with a price target range of $55-$90, despite analysts' higher expectations. Current stock price is $75.22.
The bearish sentiment among significant investors, as indicated by options trading, suggests a potential short-term downside for VKTX. However, the discrepancy between this sentiment and the more optimistic analyst price targets introduces uncertainty. The current RSI indicator and the upcoming earnings release further complicate the short-term outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100